Esterlis, I
DellaGioia, N
Pietrzak, R H
Matuskey, D
Nabulsi, N
Abdallah, C G
Yang, J
Pittenger, C http://orcid.org/0000-0003-2117-9321
Sanacora, G
Krystal, J H
Parsey, R V
Carson, R E
DeLorenzo, C
Article History
Received: 1 September 2016
Revised: 28 November 2016
Accepted: 24 January 2017
First Online: 11 April 2017
Competing interests
: JHK: (1) Vladimir, Coric, Krystal, John H, Sanacora, Gerard—Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: 15 July 2014. (2) Charney D, Krystal JH, Manji H, Matthew S, Zarate C—Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on 5 March 2014; United States application or PCT International application No. 14/306,382 filed on 17 June 2014. He was also on consultant/advisory board for: AMGEN, AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Forum Pharmaceuticals, Janssen Research & Development, Otsuka America Pharmaceutical, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Blackthorn Therapeutics, Inc., Lohocla Research Corporation, Luc Therapeutics, Inc., Pfizer Pharmaceuticals, and TRImaran Pharma. GS has received consulting fees form Allergan, Alkermes, AstraZeneca, BioHaven Pharmaceuticals, Hoffman La-Roche, Janssen, Merck, Naurex, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valenant pharmaceutical North America and Vistagen therapeutics over the past 24 months. He has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Johnson & Johnson, Hoffman La-Roche, Merck & Co., Naurex and Servier over the past 24 months. Free medication was provided to GS for an NIH sponsored study by Sanofi-Aventis. In addition, he holds shares in BioHaven Pharmaceuticals Holding Company and is a co-inventor on a patent ‘Glutamate agents in the treatment of mental disorders’ Patent number: 8778979. RHP: Scientific Consultant to Cogstate, Ltd. CGA served on advisory boards for Genentech. REC received research support from Astra-Zeneca, Astellas, BMS, Pfizer, Siemens, Taisho and UCB. The other authors declare no conflict of interest.